Anti-(+)—methamphetamine monoclonal antibodies

• US 9,023,353 B2
• Filed: 03/13/2013
• Issued: 05/05/2015
• Est. Priority Date: 03/13/2013
• Status: Active Grant

• Current Assignee: Bioventures, LLC
• Original Assignee: The Board of Trustees of the University of Arkansas (University of Arkansas System)
• Inventors: Owens, Samuel Michael, Henry, Ralph, Brown, Alicia
• Primary Examiner(s): HUYNH, PHUONG N
• Application Number:
  US13/802,688
• Publication Number:
  US 20140271686A1
• Time in Patent Office: 783 Days
• Field of Search: None
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: C07K 16/44 against material not provided for elsewhere , e.g. haptens, metals, DNA, RNA, amino acids
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/90 characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention encompasses compositions and methods for effectively treating at least one symptom or sign of methamphetamine use, or for slowing the rate of (+) methamphetamine entry into the brain of a subject. The method comprises administering an effective amount of an anti-(+) methamphetamine antibody to a subject.

Claims

1. An isolated antibody, wherein the antibody specifically binds (+) methamphetamine and comprises:

(a) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO;

5;

(b) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO;

6;

(c) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO;

7;

(d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO;

8;

(e) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO;

9; and

(f) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO;

10.

2. The isolated antibody of claim 1, wherein the antibody is encoded by a nucleic acid sequence comprising a sequence selected from the group consisting of SEQ ID NO:

1 and SEQ ID NO;

2.

3. The isolated antibody of claim 1, wherein the antibody is selected from the group consisting of a single-chain antibody, an immunologically effective antibody fragment thereof, a chimeric antibody, and a humanized antibody.

4. A method for treating at least one medical problem associated with methamphetamine use in a subject which comprises administering an effective amount of the antibody of claim 1 to the subject to treat at least one medical problem.

5. The method of claim 4, wherein the treating includes attenuating, reversing, or improving at least one symptom or sign of methamphetamine use in a subject.

6. The method of claim 4, wherein the medical problem associated with methamphetamine use is selected from the group consisting of methamphetamine addiction and methamphetamine abuse.

7. The method of claim 4, wherein the medical problem associated with methamphetamine use is selected from the group consisting of acute methamphetamine overdose, chronic methamphetamine overdose, and methamphetamine-use relapse.

8. The method of claim 4, wherein the anti-(+) methamphetamine antibody binds an epitope within (+) methamphetamine, a metabolite of (+) methamphetamine, or (+) methamphetamine-like analog.

9. The method of claim 4, wherein the antibody slows the rate of (+) methamphetamine entry into the brain of a subject.

10. The method of claim 4, wherein the antibody reduces the frequency of methamphetamine use relapse in a subject addicted to methamphetamine.

11. An isolated bispecific antibody, wherein the antibody specifically binds at least (+) methamphetamine and comprises:

(a) a light chain CDR1 comprising the amino acid sequence of SEQ ID NO;

5;

(b) a light chain CDR2 comprising the amino acid sequence of SEQ ID NO;

6;

(c) a light chain CDR3 comprising the amino acid sequence of SEQ ID NO;

7;

(d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO;

8;

(e) a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO;

9; and

(f) a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO;

10.